Track the 万泰生物 stock price and the full insider trade history of the company, a listed issuer based in China. Shares are quoted on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 万泰生物 has recorded 21 public disclosures. Market capitalisation: €37.5bn. The latest transaction was reported on 28 May 2025 (Sale). Among the most active insiders: 赵义勇. All data is accessible without an account.
21
Insider Decl.
n/a
Thresholds
€2,491
1 ops.
Buy Volume
€111m
20 ops.
Sell Volume
11Σ signal
Buys €2,491€111m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,673 of 28,836 companies
31.7
score / 100
Value
30
Quality
34
FCF yld-1.9%
Earn yld-1.1%
EV/EBITDA·
ROE-3.3%
Gross mgn49%
Net mgn-22%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
万泰生物 is a company in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and manufacturing of biological products and diagnostics.
